Trial Parameters
Brief Summary
This is an open label, single-arm, multicenter phase 1b study of stable adult liver transplant recipients on a tacrolimus (TAC)-based immunosuppression (IS) regimen who will transition from TAC to Everolimus (EVR), receive five doses of EPO and concurrently initiate phased withdrawal from EVR. The primary objective is to test the safety of administering Everolimus (EVR) and epoetin alfa (EPO) to induce operational tolerance in stable adult liver transplant recipients
Eligibility Criteria
Inclusion Criteria: 1. Subject must be able to understand and provide informed consent 2. 1-10 years post-liver transplant 3. Tacrolimus-containing maintenance immunosuppression (IS) regimen without corticosteroid. Mycophenolate mofetil (MMF) dose must be \<=2000 mg daily or mycophenolic acid (MPA) dose\<=1440 mg daily (if on MMF or MPA). Tacrolimus level must be \<8 ng/ml on the 2 most recent laboratory results within 3 months. 4. Gamma glutamyl transferase (GGT) and alanine transaminase (ALT) \<= upper limit of normal (ULN) 5. Estimated glomerular filtration rate (GFR) \>=40 mL/min/1.73 m\^2 using the CKD-EPI 2021 equation 6. Female subjects of reproductive potential must have a negative pregnancy test upon study entry 7. Female subjects with reproductive potential, must agree to use Food and Drug Administration (FDA)-approved methods of birth control for the duration of the study 8. Subjects must have current vaccinations or documented immunity as per the Division of Allergy, Immuno